Please login to the form below

Not currently logged in
Email:
Password:

Genesis Biopharma names Hans Bishop as chair

Former chief operating officer of Dendreon joins specialist in cancer immunotherapies

Former chief operating officer of Dendreon Hans Bishop has been appointed executive chair of the board at Genesis Biopharma.

The US biotech specialises in cancer immunotherapies and Bishop first joined Genesis as a director in the beginning of 2012.

He will take over from Anthony Cataldo who will remain at the firm as a director.

“To support our business plan we have been expanding our leadership with talented, experienced professionals,” said Cataldo.

“The addition of Hans as our executive chair further enhances this dynamic team as he is a proven leader with an impressive track record of enhancing operational and financial results.”

Prior to his role at Dendreon, Bishop served as president of Bayer's speciality medicine business division from 2006 until 2009, leading units in oncology, neurology, ophthalmology and haematology.

From 2004 to 2006 he held the position of senior VP, global commercial operations for Chiron Corporation, now part of Novartis.

Commenting on his appointment, Bishop said: “It is a privilege to serve as executive chair of Genesis Biopharma at this important point in the company's evolution.  I look forward to building a strong leadership team & working with my colleagues on the board to steer the company to success.”

30th March 2012

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
mXm Medical Communications

mXm Medical Communications meets the needs of pharmaceutical marketers and medics who require a highly experienced, bespoke service from their...

Latest intelligence

Beyond the event
...
Anthill Agency and Actando partnership to Transform Pharma's Digital Skills
Anthill Agency, a leading life sciences digital agency, today announced the launch of the Anthill Academy™ and partnership with Actando's PharmAcademy....
Is the pharma business model ready for precision medicine?
Precision medicine promises to revolutionise patient outcomes and reduce costs for industry but is pharma ready for it? Blue Latitude Health co-founder Head of Strategy Fred Bassett explores the challenges...

Infographics